Please use this identifier to cite or link to this item:
|Title:||Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019.|
|Authors:||Lau, David K;Burge, Matthew;Roy, Amitesh;Chau, Ian;Haller, Daniel G;Shapiro, Jeremy D;Peeters, Marc;Pavlakis, Nick;Karapetis, Christos S;Tebbutt, Niall C;Segelov, Eva;Price, Timothy J|
|Affiliation:||GI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom|
Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Dept of Surgery, University of Melbourne, Melbourne, Australia
Medical Oncology, Monash Medical Centre, Clayton, Australia
Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia
Medical Oncology, Flinders Medical Centre, Bedford Park, Australia
Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia
University of Queensland, Brisbane, Australia
Monash University, Melbourne, Australia
Medical Oncology, Cabrini Medical Centre, Melbourne, Australia
Medical Oncology, Royal North Shore Hospital, St Leonards, Australia
Sydney University, Camperdown, Sydney, Australia
GI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom..
Medical Oncology, University Hospital Antwerp, Oncology, Edegem, Belgium..
|Citation:||Expert review of anticancer therapy 2020; online first: 18 March|
|Abstract:||Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behaviour according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarises expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumours. Clinically distinct treatment pathways based on tumour RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12C mutation and gene TRK fusion defects.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.